Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation
Part of paid clinical trials in Ann Arbor, Michigan.
- Sponsor
- Muhammad N Aslam, MD
- Study ID
- NCT07501078
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Ileal Pouch
- Ulcerative Colitis
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Aquamin — DRUGParticipants will take 2400 milligrams of Aquamin (containing approximately 800 milligrams calcium/day) per day (2 capsules in the morning, two capsules in the evening, or all 4 at one time), oral administration, for 365 days. If participants cannot swallow capsule whole, the capsule may be opened and mixed into liquid or soft food (e.g., water or applesauce) to be consumed. Participants will also take lactulose and mannitol on days day 0, day 180, and day 365 to measure the lactulose:mannitol ratio to assess gastrointestinal permeability.
- Placebo — DRUGParticipants will take 4 capsules per day; 2 to be taken in the morning and 2 in the evening or all 4 at once. Participants will take this for 365 days. If participants cannot swallow capsule whole, the capsule may be opened and mixed into liquid or soft food (e.g., water or applesauce) to be consumed. Participants will also take lactulose and mannitol on days day 0, day 180, and day 365 to measure the lactulose:mannitol ratio to assess gastrointestinal permeability.
Study Details
Ulcerative colitis (UC) is a disease that causes long-term inflammation in the digestive tract, and many people with this condition require surgery to remove the colon and create a new J-pouch for stool. Some patients develop a problem called pouchitis, where this pouch becomes inflamed. Current treatments are limited, and there are no known ways to prevent pouchitis from starting. This study is being done to find out if a natural mineral supplement called Aquamin® can help reduce inflammation and protect the gut lining in people with a J-pouch, and may reduce the risk of pouchitis. By understanding whether Aquamin® is safe and helpful, the study team hopes to find a new and better way to prevent inflammation and improve the long-term health of people with UC.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- Mar 2026
- Primary completion
- May 31, 2029
- Completion
- May 31, 2029
Study Design
- Enrollment
- 52 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Aquamin
- Placebo Comparator: Placebo
Primary Outcome Measure
Time to clinical onset of pouchitis using the Modified Pouchitis Disease Activity Index (mPDAI) clinical symptoms section [ Time Frame: Baseline up to day 365 ]
Central Contacts
- Lauren Manning734-615-7236
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Michigan | Ann Arbor | Michigan | 48109 | Muhammad N Aslam, MBBS, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Ann Arbor, MI
Related Studies
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisPHASE2 · Recruiting · Pfizer · Little Rock, Arkansas
- Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)PHASE1/PHASE2 · Recruiting · Exegi Pharma, LLC · Los Angeles, California